Patent ID: 9657108
Date: 2017-05-23
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method of administering a mixture of three monoclonal IgG1 anti-EGFR antibodies to a human cancer patient, the method comprising initially administering the mixture to the patient as a first and a second intravenous infusion over a two week cycle as priming doses in sequence as set forth in the following table: wherein the 1 wherein the 2 wherein, prior to each infusion of the mixture of anti-EGFR antibodies, diphenhydramine is administered to the patient orally or intravenously at a dose of 25 mg-50 mg and methylprednisolone is administered to the patient intravenously at a dose of 25-125 mg; and wherein the mixture comprises: i) a first monoclonal antibody comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 7, 8 and 9 respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 10, 11 and 12 respectively; ii) a second monoclonal antibody comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 13, 14 and 15 respectively and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 16, 17, and 18 respectively; and iii) a third monoclonal antibody comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 19, 20 and 21 respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 22, 23 and 24 respectively; wherein the first antibody, the second antibody, and the third antibody are formulated in a mixture at a molar ratio to each other of 2:2:1, respectively; wherein the mixture of three monoclonal IgG1 anti-EGFR antibodies is administered to a human cancer patient diagnosed with colorectal cancer, in combination with liposomal irinotecan.